Jack Egan has been the Vice President of Manufacturing and Development since June 2022. Prior to that time, Dr. Egan served as the Vice President of Manufacturing and Quality Control and the Senior Director, Process and Assay Development. Before joining our Company, Dr. Egan served as the Director of Upstream Process Development and Assay Development at Altor BioScience Corporation following its April 2017 acquisition by NantCell, Inc. (which subsequently became ImmunityBio, Inc.) until 2019. Prior to that, he was a Senior Scientist and later the Director of Process Development and Quality Control at Altor BioScience Corporation from its inception in 2002 until its acquisition by NantCell, Inc. in 2017. During his time at Altor/NantCell Dr Egan was an integral part of the team that conceived and developed ALT-803 (later known as N-803 and Anktiva) which was recently approved for commercialization by the USFDA. His contributions in the development of this therapeutic molecule include preclinical research as well as analytical and upstream process development and manufacturing. From 2000 to 2002, Dr. Egan was a Senior Scientist at Sunol Molecular Corporation; and from 1998 to 2000, he was a Scientist at Centeon/Aventis Behring. Dr. Egan received his B.S. degree in Genetics and Cell Biology at the University of Minnesota and his Ph.D. in Molecular and Cell Biology at the University of Vermont. Additionally, he was a postdoctoral fellow at the University of Vermont. Dr. Egan is also a retired U.S. Army Reserve Colonel.